Actualizar mis citas con la selección
Presentar
resultados
Newman CB, Preiss D, Tobert JA, Jacobson TA, Page II RL, Goldstein LB, Chin C, Tannock LR, Miller M, Raghuveer G, Duell PB, Brinton EA, Pollak A, Braun LT, Welty FK.
Statin safety and associated adverse events: a scientific statement from the American Heart Association.
Arteriosclerosis, Thrombosis, and Vascular Biology 2019;39:enero. [Ref.ID 103011]
Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, Brochado AR, Fernandez KC, Dose H, Mori H, Patil KR, Bork P, Typas A.
Extensive impact of non-antibiotic drugs on human gut bacteria.
Nature 2018;555:29 de marzo. [Ref.ID 102577]
Weisz G, Généreux P, Iniguez A, Zurakowski A, Shechter M, Alexander KP, Dressler O, Osmukhina A, James S, Ohman EM, Ben-Yehuda O, Farzaneh-Far R, Stone GW, for the RIVER-PCI Investigators.
Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial.
Lancet 2016;387:136-45. [Ref.ID 100087]
18.
Miselli M.
Ranolazina.
Informazioni sui Farmaci 2010;34:49-51. [Ref.ID 89059]
Actualizar mis citas con la selección